1. Home
  2. AMBQ vs ARVN Comparison

AMBQ vs ARVN Comparison

Compare AMBQ & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AMBQ

Ambiq Micro Inc.

HOLD

Current Price

$80.28

Market Cap

594.9M

Sector

Technology

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.84

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMBQ
ARVN
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
594.9M
658.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
AMBQ
ARVN
Price
$80.28
$7.84
Analyst Decision
Buy
Buy
Analyst Count
5
19
Target Price
$42.20
$15.05
AVG Volume (30 Days)
876.5K
790.3K
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
N/A
$262,600,000.00
Revenue This Year
$41.81
N/A
Revenue Next Year
$27.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.12
$6.06
52 Week High
$85.72
$14.22

Technical Indicators

Market Signals
Indicator
AMBQ
ARVN
Relative Strength Index (RSI) 70.86 23.97
Support Level $25.90 $7.35
Resistance Level $85.72 $8.22
Average True Range (ATR) 5.98 0.43
MACD -0.34 -0.08
Stochastic Oscillator 74.59 2.99

Price Performance

Historical Comparison
AMBQ
ARVN

About AMBQ Ambiq Micro Inc.

Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: